Tyler Dunlap, Pharm.D., DABCP

Research Scientist II

Tyler joined MetrumRG in 2023 after earning his Doctor of Pharmacy from the University of Missouri – Kansas City and completing fellowship training in pharmacometrics/clinical pharmacology at the University of North Carolina at Chapel Hill. His primary research interests are in modeling the relationships between tumor growth, new lesion appearance, and overall survival in patients with solid tumors. He is passionate about pharmacometrics education and dose-optimization in oncology.

Recent publications by this scientist

OptiDose with mrgsolve for efficacy and safety-driven dose optimization

September 16, 2025

Presented at ACCP Annual Meeting 2025. This work showcases the OptiDose method in mrgsolve, enabling efficient and systematic optimization of dosing regimens with respect to both efficacy and safety considerations. By optimizing across multiple clinical endpoints and patient preferences, these model-informed strategies can guide patient-centered dosing decisions in oncology.

Download PDF

Incorporating PGx into Population PK Modeling

September 13, 2025

Presented at the PGRN 2025 Scientific Meeting, held in collaboration with ClinPGx, September 10–12, 2025 at the University of Montana in Missoula, where together leaders in pharmacogenomics and clinical pharmacology came together to advance the science and practice of precision medicine.

Pharmacogenetics (PGx) provides critical insights into how genetic variability influences drug metabolism, disposition, and response. This presentation highlights how when incorporated into population PK models, PGx information can:

  • Identify subgroups with distinct pharmacokinetic profiles
  • Improve predictions of individual dose–response relationships
  • Support precision dosing strategies that optimize efficacy while minimizing toxicity

Integrating PGx into quantitative modeling is a powerful step toward making personalized medicine a clinical reality.

Download PDF